Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfs25-IMX313/Matrix-M1 in healthy adults
NCT04130282Phase 1Terminated
- Sponsor
- University of Oxford
- Start
- Sep 2019
- Primary completion
- Sep 2020
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Pfs25-IMX313 in Malaria, sponsored by University of Oxford. Primary endpoint: Assessment of safety and reactogenicity at 8 months. Started Sep 2019; status: terminated.
02
Drugs
Pfs25-IMX313
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT04130282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130282.